These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22569849)

  • 21. Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists.
    Sebastianutto I; Maslava N; Hopkins CR; Cenci MA
    Neurobiol Dis; 2016 Dec; 96():156-170. PubMed ID: 27597526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo electrophysiological assessment of the agonistic properties of flibanserin at pre- and postsynaptic 5-HT1A receptors in the rat brain.
    Rueter LE; de Montigny C; Blier P
    Synapse; 1998 Aug; 29(4):392-405. PubMed ID: 9661257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.
    Cortés M; Malave L; Castello J; Flajolet M; Cenci MA; Friedman E; Rebholz H
    J Neurosci; 2017 Dec; 37(49):11930-11946. PubMed ID: 29097596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
    Johnston TH; Geva M; Steiner L; Orbach A; Papapetropoulos S; Savola JM; Reynolds IJ; Ravenscroft P; Hill M; Fox SH; Brotchie JM; Laufer R; Hayden MR
    Mov Disord; 2019 May; 34(5):708-716. PubMed ID: 30575996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
    Bezard E; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study.
    LeWitt PA; Stebbins GT; Christensen KV; Tan R; Pretorius A; Thomsen M
    Mov Disord; 2024 Mar; 39(3):613-618. PubMed ID: 38314643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
    Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
    Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
    McCreary AC; Varney MA; Newman-Tancredi A
    Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Yin LL; Geng XC; Zhu XZ
    Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
    Smith LA; Jackson MJ; Johnston L; Kuoppamaki M; Rose S; Al-Barghouthy G; Del Signore S; Jenner P
    Clin Neuropharmacol; 2006; 29(3):112-25. PubMed ID: 16772809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Buspirone in levodopa-induced dyskinesias.
    Bonifati V; Fabrizio E; Cipriani R; Vanacore N; Meco G
    Clin Neuropharmacol; 1994 Feb; 17(1):73-82. PubMed ID: 8149361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats.
    Tani Y; Ogata A; Koyama M; Inoue T
    Eur J Pharmacol; 2010 Dec; 649(1-3):218-23. PubMed ID: 20858480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhang H; Ma L; Wang F; Chen J; Zhen X
    Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.
    Huot P; Johnston TH; Fox SH; Newman-Tancredi A; Brotchie JM
    Neuropharmacology; 2015 Oct; 97():306-11. PubMed ID: 26071982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.
    Pilleri M; Antonini A
    Expert Opin Drug Saf; 2015 Feb; 14(2):281-94. PubMed ID: 25483147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Gerlach M; Bartoszyk GD; Riederer P; Dean O; van den Buuse M
    J Neural Transm (Vienna); 2011 Dec; 118(12):1733-42. PubMed ID: 21253782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease.
    Rascol O
    J Neurol; 2000 Apr; 247 Suppl 2():II51-7. PubMed ID: 10991666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias.
    Bédard P; Parkes JD; Marsden CD
    Br Med J; 1978 Apr; 1(6118):954-6. PubMed ID: 638546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.